Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
Severe asthma is associated with significant morbidity and mortality despite the maximal use of inhaled corticosteroids and additional controller medications, and has a high economic burden. Biologic therapies are recommended for the management of severe, uncontrolled asthma to help to prevent exacerbations and to improve symptoms and health-related quality of life. The effective management of severe asthma requires consideration of clinical heterogeneity that is driven by varying clinical and inflammatory phenotypes, which are reflective of distinct underlying disease mechanisms. Phenotyping patients using a combination of clinical characteristics such as the age of onset or comorbidities and biomarker profiles, including blood eosinophil counts and levels of fractional exhaled nitric oxide and serum total immunoglobulin E, is important for the differential diagnosis of asthma. In addition, phenotyping is beneficial for risk assessment, selection of treatment, and monitoring of the treatment response in patients with asthma. This review describes the clinical and inflammatory phenotypes of asthma, provides an overview of biomarkers routinely used in clinical practice and those that have recently been explored for phenotyping, and aims to assess the value of phenotyping in severe asthma management in the current era of biologics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 12(2024), 4 vom: 09. Apr., Seite 809-823 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bourdin, Arnaud [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Asthmatic Agents |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2024.01.023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367708612 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367708612 | ||
| 003 | DE-627 | ||
| 005 | 20240409232359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240128s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2024.01.023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM367708612 | ||
| 035 | |a (NLM)38280454 | ||
| 035 | |a (PII)S2213-2198(24)00075-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bourdin, Arnaud |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Severe asthma is associated with significant morbidity and mortality despite the maximal use of inhaled corticosteroids and additional controller medications, and has a high economic burden. Biologic therapies are recommended for the management of severe, uncontrolled asthma to help to prevent exacerbations and to improve symptoms and health-related quality of life. The effective management of severe asthma requires consideration of clinical heterogeneity that is driven by varying clinical and inflammatory phenotypes, which are reflective of distinct underlying disease mechanisms. Phenotyping patients using a combination of clinical characteristics such as the age of onset or comorbidities and biomarker profiles, including blood eosinophil counts and levels of fractional exhaled nitric oxide and serum total immunoglobulin E, is important for the differential diagnosis of asthma. In addition, phenotyping is beneficial for risk assessment, selection of treatment, and monitoring of the treatment response in patients with asthma. This review describes the clinical and inflammatory phenotypes of asthma, provides an overview of biomarkers routinely used in clinical practice and those that have recently been explored for phenotyping, and aims to assess the value of phenotyping in severe asthma management in the current era of biologics | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biologic | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Eosinophil | |
| 650 | 4 | |a Fractional exhaled nitric oxide | |
| 650 | 4 | |a Phenotyping | |
| 650 | 4 | |a Severe asthma | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Brusselle, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Couillard, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Fajt, Merritt L |e verfasserin |4 aut | |
| 700 | 1 | |a Heaney, Liam G |e verfasserin |4 aut | |
| 700 | 1 | |a Israel, Elliot |e verfasserin |4 aut | |
| 700 | 1 | |a McDowell, P Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Menzies-Gow, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Patrick D |e verfasserin |4 aut | |
| 700 | 1 | |a Petousi, Nayia |e verfasserin |4 aut | |
| 700 | 1 | |a Quirce, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Schleich, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Pavord, Ian D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 12(2024), 4 vom: 09. Apr., Seite 809-823 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:4 |g day:09 |g month:04 |g pages:809-823 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2024.01.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 4 |b 09 |c 04 |h 809-823 | ||